BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 23021243)

  • 1. Chapter four--Design of improved oncolytic adenoviruses.
    Alemany R
    Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chapter three--Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds.
    Wold WS; Toth K
    Adv Cancer Res; 2012; 115():69-92. PubMed ID: 23021242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.
    Cerullo V; Koski A; Vähä-Koskela M; Hemminki A
    Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
    Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
    Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus.
    Hamada K; Zhang T; Desaki J; Nakashiro K; Itoh H; Tani K; Koyama Y; Hamakawa H
    J Gene Med; 2010 Jun; 12(6):545-54. PubMed ID: 20527047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
    Guse K; Dias JD; Bauerschmitz GJ; Hakkarainen T; Aavik E; Ranki T; Pisto T; Särkioja M; Desmond RA; Kanerva A; Hemminki A
    Gene Ther; 2007 Jun; 14(11):902-11. PubMed ID: 17377596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in oncolytic adenovirus therapies for cancer.
    Rosewell Shaw A; Suzuki M
    Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
    Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
    Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic adenoviruses for the treatment of brain tumors.
    Gomez-Manzano C; Fueyo J
    Curr Opin Mol Ther; 2010 Oct; 12(5):530-7. PubMed ID: 20886384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo.
    Dong X; Qu W; Ma S; Zhu Z; Zheng C; He A; Karlsson A; Xu K; Zheng X
    Cancer Lett; 2013 Jan; 328(1):95-103. PubMed ID: 23000515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
    Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
    Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction to Oncolytic Virotherapy.
    Engeland CE; Bell JC
    Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus combinations and chemotherapy for the treatment of human cancers.
    Kumar S; Gao L; Yeagy B; Reid T
    Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
    Todo T
    Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated cancer gene therapy and virotherapy (Review).
    Fukazawa T; Matsuoka J; Yamatsuji T; Maeda Y; Durbin ML; Naomoto Y
    Int J Mol Med; 2010 Jan; 25(1):3-10. PubMed ID: 19956895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
    Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.
    Nettelbeck DM
    J Mol Med (Berl); 2008 Apr; 86(4):363-77. PubMed ID: 18214411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences.
    Sugio K; Sakurai F; Katayama K; Tashiro K; Matsui H; Kawabata K; Kawase A; Iwaki M; Hayakawa T; Fujiwara T; Mizuguchi H
    Clin Cancer Res; 2011 May; 17(9):2807-18. PubMed ID: 21346145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.